The XIENCE Xpedition everolimus eluting coronary stent system, which is used to treat coronary artery disease, provides enhanced deliverability with the clinical outcomes of XIENCE V and XIENCE PRIME, the company said.

Abbott Vascular chief medical officer and Medical Affairs divisional vice president Charles Simonton said the new system helps physicians in Europe to address the challenges of treating patients with complex coronary artery disease.

"With XIENCE Xpedition, Abbott continues its commitment to advancing drug eluting stent technology to improve product performance and patient outcomes," Simonton added

The CE Mark approval allows the company to launch and sell the product in the European market and in the countries recognizing the mark.

Expanded indications also form part of the approval aimed at treating patients with complex disease having a minimum duration of three months of dual anti-platelet therapy.